What family of peptides does Livagen belong to?

Livagen is one of the short Khavinson peptide bioregulators developed in Russia, in the same class as Epitalon and the Cytogen-series organ peptides, studied for tissue-specific gene regulation.

Is there clinical evidence for Livagen?

Evidence is largely preclinical and from cell-culture and small Russian studies; robust controlled human trials are lacking, so it remains a research compound.

← All peptides

Longevity & Anti-aging

Research Chemical

Livagen

Also known as: Livagen

Livagen is a short synthetic peptide (Lys-Glu-Asp-Ala) developed in Russian peptide bioregulator research, studied for liver function and chromatin activation. It is positioned within the longevity and anti-aging space.

Mechanism of Action

Livagen is a tetrapeptide bioregulator believed to act as an epigenetic modulator that binds AT-rich regions of DNA and promotes chromatin decondensation, restoring transcriptional activity in aging or senescent cells. In lymphocyte studies it reactivated heterochromatinized genes such as those on the inactive X chromosome and ribosomal gene clusters, increasing protein synthesis capacity. It is proposed as an organ-targeted bioregulator that normalizes hepatocyte and immune cell function during aging.

Half-life: Short, on the order of minutes for the unmodified tetrapeptide
Administration Routes: subcutaneous, intramuscular
Research Status: Research Chemical